Literature DB >> 1800369

The effect of ceftriaxone on the anaerobic bacterial flora and the bacterial enzymatic activity in the intestinal tract.

G W Welling1, G J Meijer-Severs, G Helmus, E van Santen, R H Tonk, H G de Vries-Hospers, D van der Waaij.   

Abstract

The normal flora of the intestinal tract, mainly consisting of anaerobic bacteria, protects the host against colonization by pathogenic microorganisms. Antimicrobial treatment with ceftriaxone may influence the colonic microflora and as a consequence, the protective effect. Ten healthy volunteers received 1 g of ceftriaxone intramuscularly for five days. This resulted in a significant decrease (p less than 0.05) of the mean cultural counts (+/- SEM) of total anaerobes from 10.67 (0.11) (prior to treatment) to 9.02 (0.45) and 8.97 (0.46) at days 3 and 5, respectively (during treatment). After treatment (days 10 and 15-19), the cultural counts of anaerobes returned to 10.17 (0.16) and 10.44 (0.18), respectively. Bacterial enzymes may serve as an indicator of protective microflora. beta- aspartylpeptidase and deoxycholate hydrolase activity was determined in faecal supernatants of the volunteers and compared with anaerobic culturing. Both enzymatic activities show a significant correlation with the total number of anaerobes present at day 3 of deftriaxone treatment. At day 5 and 8 only beta-aspartylpeptidase showed significant correlations with cultural counts of total anaerobes, Bacteroides spp. or bifidobacteria. At day 15 to 19 (ten to 14 days after treatment) beta-aspartylpeptidase showed only a significant correlation with the number of Bacteroides spp. This indicates that changes in the indigenous bacterial flora during and shortly after treatment with ceftriaxone can be monitored by determination of beta-aspartylpeptidase. Recovery of the intestinal flora is difficult to assess in this manner.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1800369     DOI: 10.1007/BF01645354

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

1.  Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization.

Authors:  F Léonard; A Andremont; B Leclerq; R Labia; C Tancrède
Journal:  J Infect Dis       Date:  1989-08       Impact factor: 5.226

Review 2.  The ecology of the human intestine and its consequences for overgrowth by pathogens such as Clostridium difficile.

Authors:  D van der Waaij
Journal:  Annu Rev Microbiol       Date:  1989       Impact factor: 15.500

3.  Enzymatic inactivation of aztreonam by faecal enzyme preparations from healthy volunteers.

Authors:  G W Welling; G Groen; S Welling-Wester; H G de Vries-Hospers; D van der Waaij
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

4.  Ceftriaxone: renal and biliary excretion and effect on the colon microflora.

Authors:  A Arvidsson; G Alván; B Angelin; O Borgå; C E Nord
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

5.  Effect of broad-spectrum cephalosporins on the microbial flora of recipients.

Authors:  G P Bodey; V Fainstein; I Garcia; B Rosenbaum; Y Wong
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

6.  Colonization resistance of the digestive tract: clinical consequences and implications.

Authors:  D van der Waaij
Journal:  J Antimicrob Chemother       Date:  1982-10       Impact factor: 5.790

Review 7.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

8.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

9.  Comparison of methods for the determination of beta-aspartylglycine in fecal supernatants of leukemic patients treated with antimicrobial agents.

Authors:  G W Welling
Journal:  J Chromatogr       Date:  1982-10-08

10.  The screening of four aminoglycosides in the selective decontamination of the digestive tract in mice.

Authors:  D van der Waaij; J Aberson; H A Thijm; G W Welling
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

View more
  9 in total

1.  Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition.

Authors:  Stephane-M Schneider; Fernand Girard-Pipau; Jerome Filippi; Xavier Hebuterne; Dominique Moyse; Gustavo-Calle Hinojosa; Anne Pompei; Patrick Rampal
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

2.  Characterization of human faecal flora by means of an improved fluoro-morphometrical method.

Authors:  G J Jansen; M H Wilkinson; B Deddens; D van der Waaij
Journal:  Epidemiol Infect       Date:  1993-10       Impact factor: 2.451

3.  Effect of Antibiotic Treatment on the Gastrointestinal Microbiome of Free-Ranging Western Lowland Gorillas (Gorilla g. gorilla).

Authors:  Klára Vlčková; Andres Gomez; Klára J Petrželková; Christopher A Whittier; Angelique F Todd; Carl J Yeoman; Karen E Nelson; Brenda A Wilson; Rebecca M Stumpf; David Modrý; Bryan A White; Steven R Leigh
Journal:  Microb Ecol       Date:  2016-03-16       Impact factor: 4.552

4.  Healthy individuals possess circulating antibodies against their indigenous faecal microflora as well as against allogenous faecal microflora: an immunomorphometrical study.

Authors:  H Z Apperloo-Renkema; T G Jagt; R H Tonk; D van der Waaij
Journal:  Epidemiol Infect       Date:  1993-10       Impact factor: 2.451

Review 5.  Development of the infant intestinal microbiome: A bird's eye view of a complex process.

Authors:  Sharon B Meropol; Amy Edwards
Journal:  Birth Defects Res C Embryo Today       Date:  2015-12-11

6.  Models of antimicrobial pressure on intestinal bacteria of the treated host populations.

Authors:  V V Volkova; C L Cazer; Y T Gröhn
Journal:  Epidemiol Infect       Date:  2017-05-02       Impact factor: 4.434

Review 7.  Impact of antimicrobial therapy on the gut microbiome.

Authors:  Amira A Bhalodi; Tjitske S R van Engelen; Harjeet S Virk; W Joost Wiersinga
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

Review 8.  Human gut microbiota: repertoire and variations.

Authors:  Jean-Christophe Lagier; Matthieu Million; Perrine Hugon; Fabrice Armougom; Didier Raoult
Journal:  Front Cell Infect Microbiol       Date:  2012-11-02       Impact factor: 5.293

9.  The influence of the intestinal microflora to the efficacy of Rosuvastatin.

Authors:  Lijun Wang; Yang Wang; Hongwei Wang; Xue Zhou; Xianjing Wei; Zezhou Xie; Zhipeng Zhang; Keke Wang; Jianjun Mu
Journal:  Lipids Health Dis       Date:  2018-06-30       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.